Procedures

What is the Procedure for Stem Cells

After admission, the patient will meet with the attending physician for a complete evaluation. When necessary, consultation with an appropriate medical specialist will follow. Upon review of each patient’s individual medical evaluation, this detailed information will be used as a guide for choosing the protocol for stem cell therapy. All relevant laboratory and radiological examinations will be undertaken as per clinical protocol. Safety assessments will include administration of adverse events questionnaires, physical exam, and blood tests conducted at specified intervals before and after therapy. Schedule of study assessments is designed and described in every clinical protocol approved by an Institutional Review Board.

Treatment modalities

Please consult with the clinical study physician to select the administration modality optimal for your therapy.

Neurological Diseases:

  • Three treatment sessions Each session: Intravenous administration of human allogeneic umbilical cord blood mononuclear cells (350 million cells) plus Intrathecal administration of human allogeneic umbilical cord blood mononuclear cells (50 million cells).
  • Three treatment sessions Each session: Intravenous administration of human allogeneic umbilical cord blood mononuclear cells (400 million cells) in conjunction with Mannitol.
  • Three treatment sessions Each session: Intravenous administration of human allogeneic umbilical cord blood mononuclear cells (400 million cells).

Musculoskeletal diseases:

  • One treatment: Intravenous administration of human allogeneic umbilical cord blood mononuclear cells (300 million cells) plus Intra-articular administration of human allogeneic umbilical cord blood mononuclear cells (100 million cells).
  • One treatment: Intravenous administration of human allogeneic umbilical cord blood mononuclear cells (400 million cells) plus Intra-articular administration of autologous adipose tissue derived cell (30 million cells).
  • One treatment: Intra-articular administration of human allogeneic umbilical cord blood mononuclear cells (400 million cells).
  • One treatment: Intra-articular administration of autologous adipose tissue derived cell (30 million cells).

Diabetic wounds:

  • Two treatment sessions Each session: multiple injections of human allogeneic umbilical cord blood mononuclear cells (200 million cells) within and immediately surrounding the wound.

Cardiovascular diseases/Lung diseases/Liver diseases/Inflammatory bowel diseases/Kidney diseases/Metabolic diseases :

  • Three treatment sessions Each session: Intravenous administration of human allogeneic umbilical cord blood mononuclear cells (400 million cells).

Stem Cell Regenerative Skin and Scalp Treatment:

The number of sessions will depend on the skin condition
  • Injection in the face of human allogeneic umbilical cord blood mononuclear cells (100 million cells).
  • Injection in the face of human allogeneic umbilical cord blood mononuclear cells (100 million cells) plus Intravenous infusion of human allogeneic umbilical cord blood mononuclear cells (300 million cells).
  • Injection in the scalp of human allogeneic umbilical cord blood mononuclear cells (100 million cells).
  • Injection in the scalp of human allogeneic umbilical cord blood mononuclear cells (100 million cells) plus Intravenous infusion of human allogeneic umbilical cord blood mononuclear cells (300 million cells).